Trial Profile
Baseline characteristics and initial safety and efficacy outcomes of ibrutinib in patients with refractory/ralapsed chronic lymphocytic leukemia: A real-world results from termporary authorization for use program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2016 New trial record